Price$1.77-0.05 (-2.74%)
01:30 PM07:45 PM
News · 26 weeks41+33%
2025-12-072026-05-31
Mix2390d
- Insider9(39%)
- Other7(30%)
- SEC Filings4(17%)
- Earnings2(9%)
- Leadership1(4%)
Latest news
25 items- SECSEC Form 6-K filed by Waldencast plc6-K - Waldencast plc (0001840199) (Filer)
- PRWaldencast Announces Sale of Obagi Medical to BridgepointLONDON, June 01, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or "the Company") today announced that it has entered into a definitive agreement to sell its Obagi Medical dermatological skincare and aesthetics business ("Obagi Medical") to Bridgepoint, one of the world's leading mid-market investors, in a transaction valued at up to $460 million, marking a significant step in Waldencast's strategy to strengthen its balance sheet and focus on accelerating the global growth of Milk Makeup. Founded in 1988, Obagi Medical (www.obagi.com) is a pioneer in medical-grade skincare. Rooted in advanced research and skin biology, the brand offers a distinctive portfolio of both
- PRObagi Medical Shares New Data on Recent Innovations at Music City Symposium for Cosmetic Advances & Laser Education (SCALE) MeetingNEW YORK, May 15, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD), today announced new data shared at the Music City SCALE meeting taking place May 13-17 in Nashville, TN. Results from a 12-Week Open-Label Study Evaluating the Efficacy and Tolerability of Obagi NU-GEN Cellular Renewal Serum on Wrinkles, Hyperpigmentation, Radiance, Texture, Firmness, Plumpness, and Perceived Skin Age: ePoster Dr. Todd Schlessinger, MDInterim Results from a large scale Multiple Practitioner Real-World Evaluation of a Novel Hyaluronic Acid Dermal Filler in Conjunction with Medical Grade Skin Care: eP
- PRObagi and Next Health Partner to Launch "The Skin Recharge Station" Pop-Up ExperienceNEW YORK, May 14, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), has partnered with the world's most advanced and comprehensive brand of health optimization and longevity centers, Next Health, to create "The Skin Recharge Station," an innovative limited-time pop-up truck merging advanced skincare with modern wellness. The immersive experience introduces visitors to the concept of skin energy and provides education on the science behind Nicotinamide Adenine Dinucleotide (NAD+), and its role in supporting skin vitality. NAD+ is a vit
- PRObagi Medical Unveils New Mineral Sunscreen Designed to Protect Sensitive and Post-Procedure Skin*NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced the launch of its latest innovation, Sun Shield™ Mineral UV Barrier Protect Broad Spectrum SPF 40, a clinically proven mineral sunscreen designed to deliver comprehensive UV protection while supporting skin health. Formulated with 100% mineral active filters, antioxidants, ceramides, and squalane, this advanced sunscreen provides broad-spectrum UVA/UVB protection while helping to soothe, hydrate, and support the skin barrier. The lightweight, non-com
- PRWaldencast announces conclusion of SEC investigationLONDON, April 28, 2026 (GLOBE NEWSWIRE) -- Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), a global multi-brand beauty and wellness platform, announced today that it was notified by the staff of the U.S. Securities and Exchange Commission (the "SEC") that they have concluded their investigation of the Company relating to Waldencast's restatement of its financial results and material weaknesses in its internal control over financial reporting related to historical accounting practices used by Obagi Cosmeceuticals (the "Investigation") and, based on the information available as of the date of the notice, the SEC does not intend to recommend an enforcement action against Waldenc
- SECSEC Form 6-K filed by Waldencast plc6-K - Waldencast plc (0001840199) (Filer)
- PRObagi Medical Introduces NU-GEN™ Cellular Renewal Serum Designed to Visibly Rewind Skin's Age and Restore Visible YouthfulnessNEW YORK, March 24, 2026 (GLOBE NEWSWIRE) -- Obagi Medical ("Obagi"), a leader in advanced skincare innovation, the originator of medical-grade skincare and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), is proud to announce the latest innovation in advanced skin science and longevity with the launch of its newest breakthrough: Obagi NU-GEN™ Cellular Renewal Serum. A cellular renewal serum that acts like a power supply for your skin and supports its natural cellular functions. The formula is clinically proven to visibly rewind skin's age by up to six years1 by helping replenish skin cells with NAD+ and addressing nine signs of skin aging simultaneously. At the cor
- PRObagi Medical and ProMD Announce Collaboration in the ALOHA Program to Advance Clinical Evidence with Obagi® saypha® MagIQ™NEW YORK, March 19, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced a collaboration with ProMD Health as part of the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. ProMD was selected for its strong multi-location network of 17 practices and its commitment to clinical excellence, making it an ideal evaluator to rigorously examine Obagi® saypha® MagIQ™ alongside comprehensive skincare protocols across its multi-state provider base. Through this collaboration, ProMD providers will participate in a structured evaluat
- INSIDERSEC Form 3 filed by new insider Brousset Michel3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by new insider Souza Cristiano3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by new insider Thompson Motta Roberto Moses3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by Waldencast plc3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by Waldencast plc3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by Waldencast plc3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by Waldencast plc3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by Waldencast plc3 - Waldencast plc (0001840199) (Issuer)
- INSIDERSEC Form 3 filed by Waldencast plc3 - Waldencast plc (0001840199) (Issuer)
- PRWaldencast Reports Q4 2025 and FY 2025 Financial ResultsFY 2025 net revenue of $272.1 million, flat to FY 2024, and Adjusted EBITDA of $16.1 million Q4 2025 net revenue of $72.0 million, flat to Q4 2024 and Adjusted EBITDA of $6.6 million Obagi Medical sees continued revenue acceleration as a result of transformation efforts and continued brand momentum, alongside investments supporting the recent launch of its injectables platform Milk Makeup maintains U.S. consumption growth through distribution expansion, offset by softness in international markets Waldencast advanced its strategic priorities in 2025, entering medical aesthetics, and strengthening its financial flexibility through the sale of the Obagi Japan trademark and the refinancing o
- SECSEC Form 6-K filed by Waldencast plc6-K - Waldencast plc (0001840199) (Filer)
- SECSEC Form 20-F filed by Waldencast plc20-F - Waldencast plc (0001840199) (Filer)
- SECSEC Form 6-K filed by Waldencast plc6-K - Waldencast plc (0001840199) (Filer)
- PRWaldencast plc Announces Fourth Quarter and Fiscal Year 2025 Earnings DateLONDON, March 11, 2026 (GLOBE NEWSWIRE) -- Waldencast plc, (NASDAQ:WALD) ("Waldencast"), a global multi-brand beauty and wellness platform announced that its Fourth Quarter and Fiscal Year 2025 earnings will be issued in a press release on March 13, 2026, prior to U.S. market open. The Company does not plan to host a conference call to discuss results given its ongoing strategic review. About Waldencast plc Founded by Michel Brousset and Hind Sebti, Waldencast's ambition is to build a global best-in-class beauty and wellness operating platform by developing, acquiring, accelerating, and scaling conscious, high-growth purpose-driven brands. Waldencast's vision is fundamentally underpinned
- PRObagi Medical and Schweiger Dermatology Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™NEW YORK, Feb. 27, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced Schweiger Dermatology as a key partner for the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. Schweiger will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple trials and evaluation programs. "This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to introducing this innovative injectable, and we
- PRObagi Medical and It's a Secret Med Spa Announce Collaboration in the ALOHA Program to Drive Real-World Evidence for Obagi® saypha® MagIQ™NEW YORK and DALLAS, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Obagi Medical, a leading innovator in physician-dispensed skincare and aesthetic solutions and part of Waldencast plc (NASDAQ:WALD) ("Waldencast" or the "Company"), today announced It's a Secret Med Spa as a key partner in the Aesthetics Leadership with Obagi's Hyaluronic Acid (ALOHA) Program. It's a Secret Med Spa will help generate real-world data to translate the clinical safety and efficacy demonstrated in FDA pivotal trials into everyday practice across multiple locations and structured evaluation programs. "This partnership with Obagi makes perfect sense for us. They're taking a thoughtful, evidence-based approach to launching t
WALD FAQ
7 questionsWhat does Waldencast plc do?
Waldencast Acquisition Corp. focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses. It intends to identify businesses in the beauty, personal care, and wellness sectors. The company was incorporated in 2020 and is based in White Plains, New York.Where does WALD stock trade?
Waldencast plc (WALD) is listed on NASDAQ.What sector and industry is WALD in?
Waldencast plc operates in the Consumer Discretionary sector, Package Goods/Cosmetics industry.When did Waldencast plc go public?
Waldencast plc (WALD) completed its IPO in 2021.What are analysts saying about WALD?
Waldencast plc has had 8 recent analyst actions on file. The most recent action was from Jefferies: Buy with a $200.00 price target on 2026-01-14.What companies are similar to WALD?
Notable peers in the same industry include PG (Procter & Gamble Company), UL (Unilever PLC), ECL (Ecolab Inc.), CL (Colgate-Palmolive Company), HLN (Haleon plc). Compare WALD side-by-side with any of them on Quantisnow.How can I track WALD on Quantisnow?
Quantisnow aggregates Waldencast plc's SEC filings, analyst ratings, insider transactions, FDA approvals, and press releases the moment they hit the wire (Wall Street's wire, on your screen.). Follow WALD to receive live email and push alerts on every new disclosure.